These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 33093158)

  • 1. Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.
    Nagaoka K; Shirai M; Taniguchi K; Hosoi A; Sun C; Kobayashi Y; Maejima K; Fujita M; Nakagawa H; Nomura S; Kakimi K
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy.
    Nagaoka K; Sun C; Kobayashi Y; Kanaseki T; Tokita S; Komatsu T; Maejima K; Futami J; Nomura S; Udaka K; Nakagawa H; Torigoe T; Kakimi K
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.
    Nan Y; Bai Y; Hu X; Zhou K; Wu T; Zhu A; Li M; Dou Z; Cao Z; Zhang X; Xu S; Zhang Y; Lin J; Zeng X; Fan J; Zhang X; Wang X; Ju D
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39231544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
    Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and Immune Profiling of Syngeneic Mouse Models Predict Response to Immune Checkpoint Inhibitors in Gastric Cancer.
    Lee D; Choi J; Oh HJ; Ham IH; Lee SH; Nomura S; Han SU; Hur H
    Cancer Res Treat; 2023 Jan; 55(1):167-178. PubMed ID: 35609622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice.
    Du WY; Masuda H; Nagaoka K; Yasuda T; Kuge K; Seto Y; Kakimi K; Nomura S
    Gastric Cancer; 2024 Sep; 27(5):971-985. PubMed ID: 38805119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.
    Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma.
    Liu H; Zhao Q; Tan L; Wu X; Huang R; Zuo Y; Chen L; Yang J; Zhang ZX; Ruan W; Wu J; He F; Fang Y; Mao F; Zhang P; Zhang X; Yin P; Yan Z; Xu W; Lu H; Li Q; Liang M; Jia Y; Chen C; Xu S; Shi Y; Ping YF; Duan GJ; Yao XH; Han Z; Pang T; Cui Y; Zhang X; Zhu B; Qi C; Wang Y; Lv SQ; Bian XW; Liu X
    Cancer Cell; 2023 Apr; 41(4):693-710.e8. PubMed ID: 36963400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
    Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
    McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade.
    Zhao L; Pang Y; Zhou Y; Chen J; Fu H; Guo W; Xu W; Xue X; Su G; Sun L; Wu H; Zhang J; Wang Z; Lin Q; Chen X; Chen H
    Signal Transduct Target Ther; 2024 Jun; 9(1):142. PubMed ID: 38825657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer.
    Fujimori D; Kinoshita J; Yamaguchi T; Nakamura Y; Gunjigake K; Ohama T; Sato K; Yamamoto M; Tsukamoto T; Nomura S; Ohta T; Fushida S
    BMC Cancer; 2020 Oct; 20(1):1014. PubMed ID: 33081727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting GAS6/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer.
    Kim TH; Lee D; Oh HJ; Ham IH; Lee DM; Lee Y; Zhang Z; Ke D; Hur H
    Life Sci; 2023 Dec; 335():122230. PubMed ID: 37952835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
    Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer.
    Chen Y; Huang H; Li Y; Xiao W; Liu Y; Chen R; Zhu Y; Zheng X; Wu C; Chen L
    Front Immunol; 2022; 13():832230. PubMed ID: 35320940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.